## Dynamic susceptibility contrast MRI of gliomas

Neuroimaging Clinics of North America 12, 501-523 DOI: 10.1016/s1052-5149(02)00026-6

**Citation Report** 

#	Article	IF	CITATIONS
1	Perfusion imaging of high-grade gliomas: a comparison between contrast harmonic and magnetic resonance imaging. Journal of Neurosurgery, 2004, 101, 700-703.	0.9	12
2	Dynamic Magnetic Resonance Perfusion Imaging of Brain Tumors. Oncologist, 2004, 9, 528-537.	1.9	195
3	An Introduction to Dynamic Contrast-Enhanced MRI in Oncology. , 2005, , 1-22.		15
4	Magnetic Resonance Angiography Visualization of Abnormal Tumor Vasculature in Genetically Engineered Mice. Cancer Research, 2005, 65, 8218-8223.	0.4	33
6	PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiologic Clinics of North America, 2005, 43, 35-47.	0.9	112
8	Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurgical Focus, 2006, 20, E3.	1.0	230
9	Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging. Neuroradiology, 2006, 48, 773-781.	1.1	75
10	Diffusion-weighted and Perfusion MR Imaging for Brain Tumor Characterization and Assessment of Treatment Response. Radiology, 2006, 239, 632-649.	3.6	359
11	Comparison of cerebral blood volume maps generated fromT2* andT1weighted MRI data in intra-axial cerebral tumours. British Journal of Radiology, 2007, 80, 161-168.	1.0	28
12	Magnetic Resonance Imaging Determination of Tumor Grade and Early Response to Temozolomide in a Genetically Engineered Mouse Model of Glioma. Clinical Cancer Research, 2007, 13, 2897-2904.	3.2	77
13	A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR. NeuroImage, 2007, 37, S116-S119.	2.1	31
14	FAIR-TrueFISP imaging of cerebral perfusion in areas of high magnetic susceptibility differences at 1.5 and 3 Tesla. Journal of Magnetic Resonance Imaging, 2007, 25, 924-931.	1.9	38
15	Differentiation of infective from neoplastic brain lesions by dynamic contrast-enhanced MRI. Neuroradiology, 2008, 50, 531-540.	1.1	70
16	â€ <sup>~</sup> Recurrent' glioblastoma multiforme, when should we reoperate?. British Journal of Neurosurgery, 2008, 22, 452-455.	0.4	114
18	Glioma Grading by Using Histogram Analysis of Blood Volume Heterogeneity from MR-derived Cerebral Blood Volume Maps. Radiology, 2008, 247, 808-817.	3.6	147
19	Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. Radiology, 2008, 247, 490-498.	3.6	466
20	Dynamic Contrast-Enhanced Derived Cerebral Blood Volume Correlates Better With Leak Correction Than With No Correction for Vascular Endothelial Growth Factor, Microvascular Density, and Grading of Astrocytoma. Journal of Computer Assisted Tomography, 2008, 32, 955-965.	0.5	34
21	Perfusion MR imaging in adult neoplasia. , 0, , 341-368.		0

#	Article	IF	CITATIONS
22	Tumor tissue analysis by self organizing maps from combined DCE-/DSC-MRI data. , 2009, , .		1
23	Posttreatment Recurrence of Malignant Brain Neoplasm: Accuracy of Relative Cerebral Blood Volume Fraction in Discriminating Low from High Malignant Histologic Volume Fraction. Radiology, 2009, 250, 887-896.	3.6	86
24	Automatic vessel removal in gliomas from dynamic susceptibility contrast imaging. Magnetic Resonance in Medicine, 2009, 61, 1210-1217.	1.9	18
25	Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. Journal of Neuro-Oncology, 2009, 95, 1-11.	1.4	105
26	Magnetic Resonance Perfusion and Permeability Imaging in Brain Tumors. Neuroimaging Clinics of North America, 2009, 19, 527-557.	0.5	131
27	The Immunocompromised Host: Central Nervous System. , 2009, , 1315-1323.		0
28	The striate sign: peritumoural perfusion pattern of infiltrative primary and recurrent gliomas. Neurosurgical Review, 2010, 33, 193-204.	1.2	9
29	Elevated peritumoural rCBV values as a mean to differentiate metastases from high-grade gliomas. Acta Neurochirurgica, 2010, 152, 1893-1899.	0.9	51
30	Support vector machines in DSCâ€based glioma imaging: Suggestions for optimal characterization. Magnetic Resonance in Medicine, 2010, 64, 1230-1236.	1.9	27
31	Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma. Radiology, 2010, 256, 575-584.	3.6	167
32	Measurement of cerebral perfusion using MRI. Imaging in Medicine, 2010, 2, 41-61.	0.0	3
33	Differentiation of tubercular infection and metastasis presenting as ring enhancing lesion by diffusion and perfusion magnetic resonance imaging. Journal of Neuroradiology, 2010, 37, 167-171.	0.6	27
34	Assessment of glioma proliferation using imaging modalities. Journal of Clinical Neuroscience, 2010, 17, 1233-1238.	0.8	29
35	Glioma Recurrence Versus Radiation Necrosis?. Academic Radiology, 2010, 17, 282-290.	1.3	129
36	Mean intensity curve on dynamic contrast-enhanced susceptibility-weighted perfusion MR imaging – review of a new parameter to differentiate intracranial tumors. Journal of Neuroradiology, 2011, 38, 199-206.	0.6	5
37	Characterization of intracranial space-occupying lesions by 99mTc-Tetrofosmin SPECT. Journal of Neuro-Oncology, 2011, 101, 83-89.	1.4	14
38	Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery. Journal of Neuro-Oncology, 2011, 103, 575-584.	1.4	25
39	Heterogeneity in malignant gliomas: a magnetic resonance analysis of spatial distribution of metabolite changes and regional blood volume. Journal of Neuro-Oncology, 2011, 103, 663-672.	1.4	18

#	Article	IF	CITATIONS
40	Neuroradiological Viewpoint on the Diagnostics of Space-Occupying Brain Lesions. Clinical Neuroradiology, 2011, 21, 123-139.	1.0	43
41	Measurements of diagnostic examination performance and correlation analysis using microvascular leakage, cerebral blood volume, and blood flow derived from 3T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in glial tumor grading. Neuroradiology, 2011, 53, 435-447.	1.1	34
42	MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology, 2011, 53, 721-731.	1.1	72
43	Perfusion and Permeability MR Imaging of Gliomas. Technology in Cancer Research and Treatment, 2011, 10, 59-71.	0.8	27
44	Advanced imaging of brain tumors. , 2012, , 188-213.		0
45	Does MR Perfusion Imaging Impact Management Decisions for Patients with Brain Tumors? A Prospective Study. American Journal of Neuroradiology, 2012, 33, 556-562.	1.2	42
46	Quantification of cerebral tumour blood flow and permeability with T1-weighted dynamic contrast enhanced MRI: A feasibility study. Journal of Neuroradiology, 2012, 39, 227-235.	0.6	10
47	Imaging modalities in high-grade gliomas: Pseudoprogression, recurrence, or necrosis?. Journal of Clinical Neuroscience, 2012, 19, 633-637.	0.8	49
48	Quantifying heterogeneity in human tumours using MRI and PET. European Journal of Cancer, 2012, 48, 447-455.	1.3	149
49	Advanced Techniques Using Contrast Media in Neuroimaging. Magnetic Resonance Imaging Clinics of North America, 2012, 20, 699-713.	0.6	17
50	SVM-based glioma grading: Optimization by feature reduction analysis. Zeitschrift Fur Medizinische Physik, 2012, 22, 205-214.	0.6	48
51	Delayed Contrast Extravasation MRI for Depicting Tumor and Non-Tumoral Tissues in Primary and Metastatic Brain Tumors. PLoS ONE, 2012, 7, e52008.	1.1	39
52	Proton MR spectroscopy in predicting the increase of perfusion MR imaging for WHO grade II gliomas. Journal of Magnetic Resonance Imaging, 2012, 35, 543-550.	1.9	20
53	Radiation necrosis following treatment of high grade glioma—a review of the literature and current understanding. Acta Neurochirurgica, 2012, 154, 191-201.	0.9	116
55	Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging. Acta Radiologica, 2013, 54, 448-454.	0.5	101
56	Metabolic-Oncological MR Imaging of Diffuse Low-Grade Glioma: A Dynamic Approach. , 2013, , 219-234.		Ο
57	Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM. Frontiers in Oncology, 2013, 3, 258.	1.3	29
58	Validation of 18F-FDG PET at Conventional and Delayed Intervals for the Discrimination of High-Grade From Low-Grade Gliomas. Clinical Nuclear Medicine, 2013, 38, 495-500.	0.7	23

#	Article	IF	CITATIONS
59	The Role of Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging in Differentiating between Infectious and Neoplastic Focal Brain Lesions: Results from a Cohort of 100 Consecutive Patients. PLoS ONE, 2013, 8, e81509.	1.1	31
60	Progress on the diagnosis and evaluation of brain tumors. Cancer Imaging, 2013, 13, 466-481.	1.2	37
61	Correlation of diffusion tensor, dynamic susceptibility contrast MRI and 99mTc-Tetrofosmin brain SPECT with tumour grade and Ki-67 immunohistochemistry in glioma. Clinical Neurology and Neurosurgery, 2014, 116, 41-45.	0.6	34
62	Critical Role of Imaging in the Neurosurgical and Radiotherapeutic Management of Brain Tumors. Radiographics, 2014, 34, 702-721.	1.4	32
63	Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro-Oncology, 2014, 16, 280-291.	0.6	93
64	Post-Treatment Imaging Changes in Primary Brain Tumors. Current Oncology Reports, 2014, 16, 397.	1.8	31
65	Pathophysiology, Diagnosis, and Treatment of Radiation Necrosis in the Brain. Neurologia Medico-Chirurgica, 2015, 55, 50-59.	1.0	111
66	Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma. World Neurosurgery, 2015, 84, 163-172.	0.7	4
67	Delayed contrast extravasation MRI: a new paradigm in neuro-oncology. Neuro-Oncology, 2015, 17, 457-465.	0.6	66
68	The Pathophysiology of Cerebral Radiation Necrosis and the Role of Laser Interstitial Thermal Therapy. World Neurosurgery, 2015, 83, 23-26.	0.7	12
69	Principles of T <sub>2</sub> *â€weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. Journal of Magnetic Resonance Imaging, 2015, 41, 296-313.	1.9	112
70	Quantitative measurement of blood flow in paediatric brain tumours—a comparative study of dynamic susceptibility contrast and multi time-point arterial spin labelled MRI. British Journal of Radiology, 2016, 89, 20150624.	1.0	15
71	The role of diffusion tensor imaging and dynamic susceptibility perfusion MRI in the evaluation of meningioma grade and subtype. Clinical Neurology and Neurosurgery, 2016, 146, 109-115.	0.6	15
72	Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme. European Journal of Neurology, 2016, 23, 1528-1533.	1.7	14
73	Magnetic Resonance Contrast Agents for Neuroradiology. , 2016, , 183-192.		0
74	Diagnosis and treatment options for sequelae following radiation treatment of brain tumors. Clinical Neurology and Neurosurgery, 2017, 163, 1-8.	0.6	16
75	Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2. Radiologia Medica, 2018, 123, 545-552.	4.7	33
76	Biopsy Confirmed Glioma Recurrence Predicted by Multi-Modal Neuroimaging Metrics. Journal of Clinical Medicine, 2019, 8, 1287.	1.0	3

#	Article	IF	CITATIONS
77	MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas. Neuroradiology, 2019, 61, 1023-1031.	1.1	8
78	Altered regional cerebral blood flow in obstructive sleep apnea is associated with sleep fragmentation and oxygen desaturation. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2712-2724.	2.4	17
79	Specific Preoperative Dynamic Contrast-Enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of Glioblastoma Tissue and Predict Recurrence. Cureus, 2021, 13, e15528.	0.2	0
80	Anatomic, Physiologic and Metabolic Imaging in Neuro-Oncology. Cancer Treatment and Research, 2008, 143, 3-42.	0.2	8
81	Functional Imaging-Based Diagnostic Strategy: Intra-axial Brain Masses. , 2011, , 197-220.		6
82	Physical Principles of MR Perfusion and Permeability Imaging: Gadolinium Bolus Technique. , 2011, , 53-59.		4
83	Clinical Applications of MR Perfusion Imaging. , 2011, , 71-105.		2
84	Neuroimaging. Recent Results in Cancer Research, 2009, 171, 175-190.	1.8	6
85	Multimodal Imaging to Delineate Tumor Heterogeneity in Cerebral Gliomas. Open Journal of Radiology, 2014, 04, 182-189.	0.1	3
87	Glioma Grading Using Cerebral Blood Volume Heterogeneity. , 2011, , 31-43.		0
88	Recurrent Malignant Primary Brain Tumor: the Pathophysiology and Management. , 0, , .		0
89	Magnetic Resonance Imaging of Gliomas. , 0, , .		0
90	MR Imaging Evaluation of Posttreatment Changes in Brain Neoplasms. , 2014, , 603-640.		0
91	3.0T Imaging of Brain Gliomas. , 2017, , 271-319.		Ο
92	Differentiation of Brain Abscesses from Necrotic Highgrade Gliomas Using Advanced MR Imaging Techniques: A Mini Review. Journal of Neuroimaging in Psychiatry & Neurology, 2019, 04, .	0.4	1
93	Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas?. American Journal of Neuroradiology, 2005, 26, 2455-65.	1.2	109
94	Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma?. American Journal of Neuroradiology, 2006, 27, 853-8.	1.2	109
95	Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. American Journal of Neuroradiology, 2005, 26, 1967-72.	1.2	167

#	Article	IF	CITATIONS
96	Negative 18F-FET PET/CT in brain metastasis recurrence: a teaching case report. European Journal of Hybrid Imaging, 2021, 5, 21.	0.6	0
97	Advanced MR techniques in brain tumor imaging. , 0, , 9-18.		5
98	A Multi-Disciplinary Approach to Diagnosis and Treatment of Radionecrosis in Malignant Gliomas and Cerebral Metastases. Cancers, 2022, 14, 6264.	1.7	3
99	MR Vascular Fingerprinting with Hybrid Gradient–Spin Echo Dynamic Susceptibility Contrast MRI for Characterization of Microvasculature in Gliomas. Cancers, 2023, 15, 2180.	1.7	0
100	Clinical Applications of MR Perfusion Imaging. , 2023, , 119-160.		0
101	Functional Imaging-Based Diagnostic Strategy: Intra-axial Brain Masses. , 2023, , 311-343.		Ο
102	Physical Principles of Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast MRI. , 2023, , 15-34.		0